Literature DB >> 28660605

Evaluation of depressive mood and cognitive functions in patients with acromegaly under somatostatin analogue therapy.

H Alibas1, K Uluc2, P Kahraman Koytak2, M M Uygur3, N Tuncer2, T Tanridag2, D Gogas Yavuz3.   

Abstract

AIMS: Acromegaly is caused by a pituitary adenoma that releases excess growth hormone (GH) and a concomitant increase in insulin-like growth factor 1 (IGF-1). Acromegaly results not only in phenotypic changes, but also in neurologic complications as peripheral neuropathy and cognitive dysfunction. This study aimed to compare depressive mood and cognitive function in patients with acromegaly and in healthy controls as well as to determine the factors underlying cognitive dysfunction in the acromegalic patients.
MATERIALS AND METHODS: This study included 42 patients with acromegaly that were receiving somatostatin analogue therapy and 44 healthy controls. Memory, attention, visuospatial function, inhibitory function, abstract thinking, verbal fluency, and depressive mood were measured in the patients and controls.
RESULTS: Patients with acromegaly had lower learning (p = 0.01), planning (p = 0.03), complex attention and inhibitory function (p = 0.04) scores than the controls. There was no significant difference in depressive mood between the patients and controls (p > 0.05). Gamma knife radiosurgery did not negatively affect cognitive function (p > 0.05).
CONCLUSION: The present findings show that acromegaly negatively affects learning, attention, and planning.

Entities:  

Keywords:  Acromegaly; Cognitive functions; Depressive mood

Mesh:

Substances:

Year:  2017        PMID: 28660605     DOI: 10.1007/s40618-017-0722-y

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  33 in total

1.  Cognitive dysfunction in patients with pituitary tumour who have been treated with transfrontal or transsphenoidal surgery or medication.

Authors:  K A Peace; S M Orme; S J Padayatty; H P Godfrey; P E Belchetz
Journal:  Clin Endocrinol (Oxf)       Date:  1998-09       Impact factor: 3.478

2.  [Psychopathologic symptoms and personality traits in patients with florid acromegaly].

Authors:  S Richert; A Strauss; R Fahlbusch; R Oeckler; K von Werder
Journal:  Schweiz Arch Neurol Psychiatr (1985)       Date:  1987

3.  The Relationships Between Dissociation, Attention, and Memory Dysfunction.

Authors:  Osman Özdemir; Pınar Güzel Özdemir; Murat Boysan; Ekrem Yilmaz
Journal:  Noro Psikiyatr Ars       Date:  2015-03-01       Impact factor: 1.339

Review 4.  Growth hormone, insulin-like growth factor I and cognitive function in adults.

Authors:  P S van Dam; A Aleman; W R de Vries; J B Deijen; E A van der Veen; E H de Haan; H P Koppeschaar
Journal:  Growth Horm IGF Res       Date:  2000-04       Impact factor: 2.372

5.  Evidence of cognitive and neurophysiological impairment in patients with untreated naive acromegaly.

Authors:  José Leon-Carrion; Juan Francisco Martin-Rodriguez; Ainara Madrazo-Atutxa; Alfonso Soto-Moreno; Eva Venegas-Moreno; Elena Torres-Vela; Pedro Benito-López; Maria Angeles Gálvez; Francisco J Tinahones; Alfonso Leal-Cerro
Journal:  J Clin Endocrinol Metab       Date:  2010-06-16       Impact factor: 5.958

6.  Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly.

Authors:  Mark R Postma; Romana T Netea-Maier; Gerrit van den Berg; Jens Homan; Wim J Sluiter; Margreet A Wagenmakers; Alfons C M van den Bergh; Bruce H R Wolffenbuttel; Ad R M M Hermus; André P van Beek
Journal:  Eur J Endocrinol       Date:  2012-01-16       Impact factor: 6.664

7.  Psychiatric morbidity in acromegaly.

Authors:  R T Abed; J Clark; M H Elbadawy; M J Cliffe
Journal:  Acta Psychiatr Scand       Date:  1987-06       Impact factor: 6.392

Review 8.  [Somatic factors in cognitive impairment].

Authors:  T Etgen; M Brönner; D Sander; H Bickel; K Sander; H Förstl
Journal:  Fortschr Neurol Psychiatr       Date:  2009-02-16       Impact factor: 0.752

9.  Effects of previous growth hormone excess and current medical treatment for acromegaly on cognition.

Authors:  Pauline Brummelman; Janneke Koerts; Robin P F Dullaart; Gerrit van den Berg; Oliver Tucha; Bruce H R Wolffenbuttel; André P van Beek
Journal:  Eur J Clin Invest       Date:  2012-10-20       Impact factor: 4.686

10.  Neurocognitive function in acromegaly after surgical resection of GH-secreting adenoma versus naïve acromegaly.

Authors:  Juan Francisco Martín-Rodríguez; Ainara Madrazo-Atutxa; Eva Venegas-Moreno; Pedro Benito-López; María Ángeles Gálvez; David A Cano; Francisco J Tinahones; Elena Torres-Vela; Alfonso Soto-Moreno; Alfonso Leal-Cerro
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

View more
  2 in total

Review 1.  Left to themselves: Time to target chronic pain in childhood rare diseases.

Authors:  Christine B Sieberg; Alyssa Lebel; Erin Silliman; Scott Holmes; David Borsook; Igor Elman
Journal:  Neurosci Biobehav Rev       Date:  2021-03-24       Impact factor: 8.989

2.  In Vivo Characterization of Cortical and White Matter Microstructural Pathology in Growth Hormone-Secreting Pituitary Adenoma.

Authors:  Taoyang Yuan; Jianyou Ying; Chuzhong Li; Lu Jin; Jie Kang; Yuanyu Shi; Songbai Gui; Chunhui Liu; Rui Wang; Zhentao Zuo; Yazhuo Zhang
Journal:  Front Oncol       Date:  2021-04-12       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.